In summary, given that the CD169+ TAMs in breast cancer associate with lymphocytes and TLSs in primary tumors, our functional data propose that CD169+ TAMs do not promote NK, T or B cell proliferation or activation, but rather inhibit them. Here, SIGLEC1 is linked to breast carcinoma.